By Jennifer Chiou
New York, Aug. 9 - Living Cell Technologies said it obtained A$2.3 million through a sale of stock.
The Melbourne, Australia, company sold 10,454,545 million shares at A$0.22 per share.
Taylor Collison Ltd. and Shaw Stockbroking Ltd. led investors.
The company is focused on treatments for cell loss resulting from autoimmune, degenerative, inherited or traumatic conditions.
Proceeds will go towards working capital to advance regulatory applications of the company's two lead cell therapy products for Huntington's disease, NeurotrophinCell, and diabetes.
Living Cell's stock closed unchanged at A$0.235 on Tuesday.
| Issuer: | Living Cell Technologies
|
| Issue: | Common stock
|
| Amount: | A$2.3 million
|
| Shares: | 10,454,545
|
| Price: | A$0.22
|
| Investors: | Taylor Collison Ltd., Shaw Stockbroking Ltd. (co-leads)
|
| Announcement date: | Aug. 9
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
